4[1]Yonemura Y, Sugiyama K, Fushida S, et al. Treatment options for peritoneal dissemination with chemotherapy. In Yonemura Y(eds): Peritoneal dissemination——molecular mechanisms and the latest therapy. Maeda Shoten Co, Ltd Kanazawa, Japan, 1998:175. 被引量：1
5[2]Sugarbaker PH. Management of peritoneal surface malignancy: the surgeon's role. Langenbecks Arch Surg, 1999, 384: 576. 被引量：1
6[3]Yonemura Y, Sawa T, Kinoshita K, et al. Neoadjuvant chemotherapy for high-grade advanced gastric cancer. World J Surg, 1993, 17: 256. 被引量：1
7[4]Yonemura Y, Matsuki N, Sakuma H, et al. Effect of intra-arterial infusion of MMC and CDDP for gastric cancer patients with liver metastasis. Jap J Surg, 1992, 22: 253. 被引量：1
8[5]Ohoyama S. Nakajima S. Ishihara S, et al. FLEP therapy for advanced gastric cancer. In Miyazaki I and Yonemura Y(eds): Treatment strategies for advanced gastric cancer. Soft Science. Tokyo,1995:110. 被引量：1
9[6]Kern W, Brasess J, Samel S, et al. Pharmacokinetics of cisplatin and its impact on nephrotoxicity during intraoperative hyperthermic peritoneal lavage in patients with locally advanced gastric cancer. The proceedings of 2nd International Gastric Cancer Congress. 1997: 1387. 被引量：1
10[7]Elias D, Detroz B, Debaeme B, et al. Treatment of peritoneal carcinomatosis by intraperitoneal chemo-hyperthermia reliable and unreliable concepts. Hepatogastroenterology, 1994, 41: 207. 被引量：1
8Husek P. Chloroformates in gas chromatography as general purpose derivatizing agents[J]. Journal of Chromatography B ,1998,717:57-91. 被引量：1
9van den Eynde BJ, van der Bruggen P. T cell defined tumor antigens[J]. Curr Opin Immunol, 1997,9:684-693. 被引量：1
10Thurner B, Haendle I, Roder C, et al. Vaccination with mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage Ⅳ melanoma[J]. J Exp Med, 1999,190:1669-1678. 被引量：1
